Study of Caronizumab with low-dose radiation for certain cancers
Part of Cancer, Digestive system, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a combination of an immunotherapy drug (Caronizumab) and a special type of low-dose radiation (PLDR) for people with esophageal, lung, or cervical cancer that has come back or spread after initial treatment. It aims to see if the combination can help stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have esophageal, lung, or cervical cancer that has returned or spread after first-line treatment.
- You must be in generally good health (able to care for yourself and up and about for at least half the day).
- You must have at least one measurable tumor outside the brain.
- Your blood counts and organ function (kidney, liver, heart) must be within certain safe limits.
- You cannot have other active cancers or serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody drug (QL-1706) combined with a special low-dose radiation technique for people with advanced esophageal, lung, or cervical cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow disease growth.
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
This trial tests a new combination therapy for people with recurrent or metastatic esophageal squamous cell carcinoma. First, you receive immunotherapy (cadonilimab) and a targeted drug (anlotinib), followed by radiation. The goal is to see if this approach helps control the cancer.
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
This trial tests a combination of low-dose radiation, immunotherapy, chemotherapy, and intraperitoneal perfusion for gastric cancer that has spread to the abdominal lining and is not removable by surgery. It aims to see if this treatment can help control the cancer after first-line chemotherapy has stopped working.
This trial tests a combination of low-dose radiation to the intestines and immunotherapy for people whose cancer has stopped responding to standard treatments including immunotherapy. It may offer a new option when other therapies have failed.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.